Testing an immune memory boost with checkpoint therapy
Part of Cancer, Skin clinical trials.
This early study tests whether “immune recall” (training the immune system using specific vaccine-like steps) can improve how well checkpoint drugs work for advanced melanoma. It is designed mainly to see if the approach is feasible and safe, and it may help some people respond better to PD-1 (with or without CTLA-4) treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed advanced melanoma that has spread (metastatic melanoma).
- You must be age 18 or older and able to sign (or have a representative sign) consent.
- Your cancer doctor must be planning you to receive PD-1 treatment, or PD-1 plus another checkpoint drug (CTLA-4), as standard care.
- You need at least one target spot/lesion that is at least 8 mm and can be examined or sampled with a biopsy (often ultrasound-guided).
- You must have recent blood count results that show: enough white blood cells, platelets, and hemoglobin.
- You cannot have certain melanoma types (uveal or mucosal), be pregnant or breastfeeding, or have had prior whole-body treatment for metastatic melanoma (prior surgery is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial tests a special type of immune cells (gamma-delta T cells) given with either interferon or a PD-1 inhibitor for people with stage III-IV melanoma that can be removed with surgery. The goal is to see if this combination helps the immune system fight the cancer and prevent it from coming back.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.